Evidence map›Paper›PMID 42111041›Full record

ReviewNeuro-oncology practice2026

Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review.

Erika Országh, Judit Józwiak-Hagymásy, Tamás Dóczi, Dóra Mezei, Bertalan Németh, Hédi Varga, Attila Tordai, Tomas Kazda, Thierry Gorlia, Caroline Quoilin and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Erika OrszághSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Judit Józwiak-HagymásySyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Tamás DócziSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Dóra MezeiSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Bertalan NémethSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Hédi VargaSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).
Attila TordaiDepartment of Transfusion Medicine, Semmelweis University, Budapest (A.T.).ORCID https://orcid.org/0000-0001-6966-1622
Tomas KazdaDepartment of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno (T.K.).ORCID https://orcid.org/0000-0001-7288-8975
Thierry GorliaEuropean Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels (T.G., C.Q.).
Caroline QuoilinEuropean Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels (T.G., C.Q.).
Matthias PreusserDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna (M.P.).
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome (G.M.).
Marcell CsanádiSyreon Research Institute, Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glioblastoma is considered one of the deadliest malignant solid tumors. The disease severity and the treatment intensity place a significant burden on patients, their family and caregivers, and the health systems. This study aimed to review the methodological aspects and quality of economic evaluations and health economic models in glioblastoma with a special focus on Europe and North America. Methods: A search was performed covering Medline (via PubMed), Embase, Scopus, Cochrane Library, and PROSPERO. Gray literature search and snowball sampling were also conducted. Studies were eligible if they included glioblastoma patients, contained data on economic evaluations, and were in our geographical focus. The protocol was registered in PROSPERO (ID: CRD42023488181). Results: The review of 4052 records resulted in 19 peer-reviewed articles, 1 health technology assessment agency document, 2 conference posters, and 1 thesis. Most studies investigated pharmaceuticals in combination with radiotherapy ( Conclusion: Our review identified gaps in the literature related to the economic evaluations on relapsed glioblastoma patients and to comprehensive assessments using a societal perspective. We also concluded that there is a lack of relevant, high-quality, and up-to-date utility data for glioblastoma in the studies.

Indexed as

economic evaluationseconomic modelingevidence synthesisglioblastomasystematic literature review

Identifiers

PMID42111041
PMCPMC13153701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.